Japan-based Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy developed by Ionis ...
Japanese drugmaker Ono (TYO: 4528) has entered into a license agreement with USA-based Ionis Pharmaceuticals (Nasdaq: IONS) ...
OSAKA, Japan I March 11, 2025 I Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “ONO”) announced that it has ...
Piper Sandler analyst Allison Bratzel reiterated a Buy rating on IO Biotech (IOBT – Research Report) today and set a price target of $10.00.
Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains ...
William Blair analyst Myles Minter reiterated a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today. The company’s shares opened ...
Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...
Ono Pharmaceuticals is spending $280 million upfront to take the global rights of Ionis Pharmaceuticals’ asset for a rare ...
Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...
20h
Jones Financial Companies Lllp boosted its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by ...
Carlsbad: Ionis Pharma and AstraZeneca's WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback